Tranexamic Acid (TXA) is a medication used in this clinical trial to help reduce bleeding. It works by preventing the breakdown of blood clots, which can be particularly useful during and after surgery. In this study, the researchers are investigating whether using Tranexamic Acid around the time of surgery can lower the chances of melanoma coming back early after surgery. The goal is to see if this medication can improve outcomes for patients undergoing surgery for melanoma by reducing the risk of early relapse.

Melanoma – Melanoma is a type of skin cancer that begins in the melanocytes, which are the cells responsible for producing melanin, the pigment that gives skin its color. It often appears as a new mole or a change in an existing mole, characterized by asymmetry, irregular borders, multiple colors, and a diameter larger than a pencil eraser. As melanoma progresses, it can grow deeper into the skin and spread to other parts of the body, including lymph nodes and internal organs. The disease can advance from a localized stage to regional and then to distant metastasis, where cancer cells travel through the lymphatic system or bloodstream. Early stages may be confined to the skin, but as it progresses, it can invade deeper tissues and organs. The progression of melanoma is often categorized by stages, with each stage indicating the extent of spread and depth of tumor invasion.